Search
Protagonist Therapeutics Inc
PTGXAdd to Watchlist
158.630USD
+3.530+2.28%
Close 08-17 16:00（ET）Quotes delayed by 15 min
10.26BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-17The current earnings forecast score of Protagonist Therapeutics Inc is 8.57, ranking 102 out of 387 in the Biotechnology & Medical Research industry. The average price target is 91.00, with a high of 115.00 and a low of 65.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
167.154
Target Price
+7.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Protagonist Therapeutics Inc
PTGX
14
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Protagonist Therapeutics Inc's expected revenue for the next quarter?
Protagonist Therapeutics Inc's expected revenue is 240.61M.
What is Protagonist Therapeutics Inc's price target?
Analysts forecast that Protagonist Therapeutics Inc's price target is USD 91.00, with the highest forecast at USD 115.00 and the lowest forecast at USD 65.00.
How have Protagonist Therapeutics IncPTGX's recent earnings per share performed?
The market expectation was USD 2.47, while Protagonist Therapeutics IncPTGX's earnings per share (EPS) for the previous quarter was USD 0.06. EPS for the next quarter is expected at USD 2.09.
What is the analyst rating for Protagonist Therapeutics Inc?
Based on the ratings of Protagonist Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.